You are here: Industry Insights > Selexis

News List

Selexis, Inotrem Partner to Advance Inotrem’s Inflammatory Disease Program contractpharma
January 19, 2022
Inotrem will leverage Selexis’ SUREtechnology Platform, a suite of cell line development technologies.
Selexis, KBI Biopharma, Immatics Partner to Advance TCR Program contractpharma
July 01, 2021
Selexis SA and KBI Biopharma, both JSR Life Sciences companies, have signed service agreements with Immatics N.V., a clinical-stage biopharmaceutical company focused on T cell redirecting cancer immunotherapies.
SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax contractpharma
March 19, 2021
Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform, have signed a commercial license agreement to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV).
Selexis, Pandion Enter Antibody Service Agreement contractpharma
March 17, 2021
Selexis SA, a JSR Life Sciences company, has signed a service agreement with Pandion Therapeutics, Inc. to advance the development of Pandion’s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and ...
Selexis SA and BITT Enter Service Agreement contractpharma
March 11, 2021
Selexis SA and Boston Immune Technologies and Therapeutics (BITT) have entered into a service agreement to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and ...
Selexis Makes Scientific and Operational Promotions contractpharma
May 20, 2020
Myriam Adam named ops and IP VP; Séverine Fagète named cell line development services VP; and Valérie Le Fourn, research VP.
ZyVersa, Selexis and KBI Enter Devt. and Mfg. Collaboration contractpharma
September 09, 2019
To advance ZyVersa’s lead inflammasome inhibitor into clinic with Selexis and KBI’s integrated development platform.
Selexis, Hoba Therapeutics in Development Pact contractpharma
September 29, 2018
Selexis will use its SUREtechnology Platform to develop a stable, high-performance research cell bank
Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of An biospace
March 08, 2018
Selexis SA, announced today that Compugen Ltd. has taken a license to the Selexis SUREtechnology Platform™ for use in generating high-performance research cell banks (RCBs).